Kaplan Eduneering: False Claims Act: New Rules, New Risks

False Claims Act: New Rules, New Risks

The life science industry has the largest percentage of recovered funds and open investigations under the False Claims Act. They are likely to remain at the center of federal and state prosecutions, thanks to new laws, aggressive investigations and a growing army of whistleblowers.

That triad inside the life science industry is also influenced by actions and
events outside the industry. This paper will help you identify and mitigate these risks by explaining the overlapping factors that now define the business and compliance landscape for the life science industry.

For example, this paper explains how FCA has been strengthened by the recent Recovery Act and Troubled Asset Relief Program (TARP), and the Fraud Enforcement and Recovery Act (FERA), which has promised aggressive anti-fraud measures, and has provided government agencies with sharpened tools to expose and prosecute fraud and abuse of government funds.

In addition, this paper explores the four specific areas identified by the Department of Justice as priorities for investigation by its Civil Fraud Section:

Drug Promotions

Misbranding

Medicaid Fraud

Kickbacks

Please fill out the form below to access this complimentary material. The * indicates a required field.

Registration is required only once for all registration required complimentary material on this website. Cookies must be enabled in order to take advantage of this “register once” functionality.

First Name: *

Last Name: *

Phone: *

Business Email: *

Title: *

Department: *

Company: *

Address: *

City: *

State or Province: *

Country: *

Zip or Postal Code: *

Business/Industry: *

Number of Employees: *

Level of Interest: *

Kaplan EduNeering respects your privacy and registration information will not be shared or sold to a third party.

False Claims Act: New Rules, New Risks

Download Now